tiprankstipranks
Contineum Therapeutics, Inc. Class A (CTNM)
NASDAQ:CTNM
US Market

Contineum Therapeutics, Inc. Class A (CTNM) Financial Statements

154 Followers

Contineum Therapeutics, Inc. Class A Financial Overview

Contineum Therapeutics, Inc. Class A's market cap is currently ―. The company's EPS TTM is $; its P/E ratio is ―; Contineum Therapeutics, Inc. Class A is scheduled to report earnings on May 16, 2024, and the estimated EPS forecast is $-1.11. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Sep 23Dec 22
Income Statement-
Total Revenue$ 50.00M--
Gross Profit$ 50.00M--
EBIT---
EBITDA---
Net Income Common Stockholders$ 39.46M--
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 125.19M$ 135.13M$ 47.24M
Total Assets$ 130.39M$ 139.04M$ 50.64M
Total Debt$ 572.00K$ 1.12M$ 5.85M
Net Debt$ -124.62M$ -134.00M$ -41.39M
Total Liabilities$ 5.70M$ 7.57M$ 11.37M
Stockholders Equity$ 124.68M$ 131.48M$ 39.27M
Cash Flow-
Free Cash Flow$ -11.01M--
Operating Cash Flow$ -10.70M--
Investing Cash Flow$ 9.03M--
Financing Cash Flow$ -321.00K--
Currency in USD

Contineum Therapeutics, Inc. Class A Earnings and Revenue History

Contineum Therapeutics, Inc. Class A Debt to Assets

Contineum Therapeutics, Inc. Class A Cash Flow

Contineum Therapeutics, Inc. Class A Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis